drugset / Trial / NCT04416568
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
Phase 2
Active not recruiting
30 enrolled
Dana-Farber Cancer Institute
Gateway for Cancer Research · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
Timeline
- Start
- 2020-08-14
- Primary completion
- 2025-07-17
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |